Impact of a soluble phospholipase A2 inhibitor on inhaled allergen challenge in subjects with asthma.
about
The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptorsPhospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic interventionIdentification of inhibitors against interaction between pro-inflammatory sPLA2-IIA protein and integrin αvβ3.Proinflammatory secreted phospholipase A2 type IIA (sPLA-IIA) induces integrin activation through direct binding to a newly identified binding site (site 2) in integrins αvβ3, α4β1, and α5β1.Relationship between levels of secreted phospholipase A₂ groups IIA and X in the airways and asthma severity.Secreted phospholipase A2 group X overexpression in asthma and bronchial hyperresponsiveness.Lymphoid tissue phospholipase A2 group IID resolves contact hypersensitivity by driving antiinflammatory lipid mediatorsThe involvement of phospholipases A2 in asthma and chronic obstructive pulmonary diseaseImmunologic Targets in Atopic Dermatitis and Emerging Therapies: An Update.Pro-inflammatory secretory phospholipase A2 type IIA binds to integrins alphavbeta3 and alpha4beta1 and induces proliferation of monocytic cells in an integrin-dependent manner.Reductions of phospholipase A(2) inhibition of pulmonary surfactant with hyaluronan.Secretory phospholipases A2 stimulate mucus secretion, induce airway inflammation, and produce secretory hyperresponsiveness to neutrophil elastase in ferret trachea.The Future of Atopic Dermatitis Treatment.Anti-inflammatory, antioxidant, and immunomodulatory effects of curcumin in ovalbumin-sensitized rat.Secreted Phospholipase A2 Type IIA (sPLA2-IIA) Activates Integrins in an Allosteric Manner.
P2860
Q24681206-7CC50F04-2E5B-4CF4-B211-5A0F1F631041Q26997377-B809B9E1-FF73-4324-B496-7279571AFD09Q34481371-82CF0282-7EA6-4C06-B861-598380F14F08Q34801388-C69BFD6E-CA16-4DC8-9AAD-49DC53708561Q34977635-D82C9E51-4BD3-450B-B484-34421AA1044BQ36330573-002B2DB8-0C71-495D-96DC-44EB2FCE1207Q36907943-95A9C971-6E68-414B-A6C9-EE32320A3CEBQ37191456-814BFA4D-0CD3-4FA3-99FA-F6B86490F9D2Q38883893-901DA6AB-2C12-4D96-A203-2065B2D3EC21Q41985042-FED34491-E16A-417D-9F23-0AB859FB8D2BQ43119893-E7A7FAEB-1DB8-4180-9E30-D2E641454282Q46521376-D6B52CA3-3728-4D36-9B79-E596CCEA9B3FQ47880524-29EF7717-6106-4896-BE5E-920CD16C025AQ48137739-13638A8A-65CE-4768-A17A-F87325623357Q51316539-D228ED8A-46EF-4EF1-B8AA-F93471C28596
P2860
Impact of a soluble phospholipase A2 inhibitor on inhaled allergen challenge in subjects with asthma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Impact of a soluble phospholip ...... lenge in subjects with asthma.
@en
Impact of a soluble phospholip ...... lenge in subjects with asthma.
@nl
type
label
Impact of a soluble phospholip ...... lenge in subjects with asthma.
@en
Impact of a soluble phospholip ...... lenge in subjects with asthma.
@nl
prefLabel
Impact of a soluble phospholip ...... lenge in subjects with asthma.
@en
Impact of a soluble phospholip ...... lenge in subjects with asthma.
@nl
P2093
P2860
P356
P1433
P1476
Impact of a soluble phospholip ...... lenge in subjects with asthma.
@en
P2093
Alexei A Dmitrienko
Bernhardt G Zeiher
David L Bowton
Elliot Israel
Gregory D Sides
P2860
P356
10.1081/JAS-200044748
P407
P577
2005-02-01T00:00:00Z